Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
ELM-1
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
- NCT02290951 ↗
- Completed
- Regeneron Pharmaceuticals
- Standard
We haven't built an HCP commentary report on ELM-1 (odronextamab in previously treated CD20-positive B-cell malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ELM-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| YouTube | 7 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
- Interventions
- Odronextamab multiple dose levels; Odronextamab multiple dose levels
- Arms
- Part A · Experimental
- 1N Part B · Experimental
- 2N Part B · Experimental
- Enrollment
- 200
- Primary outcomes
- Safety/overall frequency of adverse events (AEs)
- Safety/dose limiting toxicities (DLTs)
- Antitumor activity as measured by the objective response rate (ORR)
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 9, 2015
- Primary completion
- Aug 21, 2025
- Results posted
- No
- Registry record
- NCT02290951 · updated Oct 10, 2025
Publications
linked from the registry- Bayly-McCredie E, Prince HM, Yannakou CK, Fiorenza S. An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma. Expert Opin Biol Ther. 2025 Apr;25(4):331-343. doi: 10.1080/14712598.2025.2479631. Epub 2025 Mar 24. PubMed 40106587
- Topp MS, Matasar M, Allan JN, Ansell SM, Barnes JA, Arnason JE, Michot JM, Goldschmidt N, O'Brien SM, Abadi U, Avivi I, Cheng Y, Flink DM, Zhu M, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Crombie JL. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044. PubMed 39786390
- Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chavez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. PubMed 35366963
- Zhu M, Olson K, Kirshner JR, Khaksar Toroghi M, Yan H, Haber L, Meagher C, Flink DM, Ambati SR, Davis JD, DiCioccio AT, Smith EJ, Retter MW. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966. doi: 10.1111/cts.13212. Epub 2022 Jan 7. PubMed 34997701